Mulți jucători din România aleg CazinoOnlineBaniReali pentru experiența lor de joc online, datorită ușurinței de utilizare. Je snadné pochopit, proč je OnlineKasinaCesko tak oblíbený mezi hráči z České republiky i regionu. Los interesados en juegos en línea apreciarán la variedad y calidad ofrecidas por casino online dinero real todos los días.
Avrupa merkezli casino siteleri yeni altyapısı, Türk oyuncular için düşük ping bağlantısı sunar.
Yepyeni özellikleriyle bettilt giriş versiyonu heyecan veriyor.
Bahis sektöründe kalitesiyle ön bahsegel plana çıkan kullanıcılarını memnun eder.
Cartesian Therapeutics Announces New Employment Inducement Grants
April 3, 2026 2026-04-03 10:04Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On April 1, 2026, the Company issued to these employees options to purchase an aggregate of 52,450 shares of the Company’s common stock with an exercise price of $6.39, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on April 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on April 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and in Phase 1/2 clinical development of juvenile dermatomyositis with plans to initiate a Phase 2 trial in myositis, specifically dermatomyositis and antisynthetase syndrome in the first half of 2026.
